Elucidate Bio Announces Joint Poster Presentation with IN8bio at ISCT 2026

Joint ISCT 2026 poster highlights spatial multi-omic analysis of GBM patients treated with γδ T cell therapy, revealing tumor microenvironment insights.

MEDFORD, MA, UNITED STATES, May 6, 2026 /EINPresswire.com/ -- Elucidate Bio, Inc., an AI-enabled biomarker discovery company, today announced an upcoming joint poster presentation with IN8bio, Inc. (Nasdaq: INAB) at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting.

Details for the ISCT 2026 presentation are as follows:
Title: Unraveling Complexity: The Impact, Interactions and Outcomes of a γδ T Cell Therapy in Glioblastoma
Presenters: Mariska A. ter Haak, Catherine P. Langford, Gulpreet Kaur, James Perna, Jason L. Weirather, Lawrence Lamb, Kate M. Rochlin
Abstract #: 1283
Session: Poster Reception #2 - Immunotherapy (CAR-T, T Reg, NK Cells etc.)
Date and Time: Thursday, May 7, 2026, 6:00 – 7:30 PM GMT

The poster presents spatial multi-omic characterization of glioblastoma (GBM) tumor microenvironment sections from patients treated with IN8bio's DeltEx DRI γδ T cell therapy or SOC using the Elucidate Discovery Engine.

About Elucidate Bio
Elucidate Bio is an AI-driven biomarker discovery partner for precision medicine. Its Synoptic Tumor Mapping approach integrates proteomic, transcriptomic, genomic, and morphologic data from the same tissue slide to deliver a unified view of the tumor-immune microenvironment. Powered by ELUCID, its proprietary AI Pathologist, Elucidate Bio enables biopharma partners to uncover mechanisms of action, identify predictive biomarkers, and stratify patients for clinical success. For more information, visit elucidatebio.com. Follow on LinkedIn.

About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s pipeline is anchored by INB-600, a novel γδ T cell engager platform with potential applications across oncology and autoimmune indications. IN8bio is also advancing INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation, and INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed glioblastoma (GBM). For more information about IN8bio, visit www.IN8bio.com.

Elucidate Bio Contact:
Gulpreet Kaur
Chief Business Officer, Elucidate Bio
gulpreet@elucidatebio.com

In8 Bio contact:
IN8bio, Inc.
Patrick McCall
646.933.5603
pfmccall@IN8bio.com

Gulpreet Kaur
Elucidate Bio
gulpreet@elucidatebio.com
Visit us on social media:
LinkedIn
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.